Who is eligible for clinical trial NCT04085029?

Participants must meet the protocol's inclusion criteria for Oligometastasis. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT04085029 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-03

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry (NCT04085029)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Duke University

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (1 items).

Location: Duke Cancer Institute Cary — Cary, North Carolina

Age range: 18 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥ 18 years of age
Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
Patient must sign study-specific informed consent

Usually NOT eligible if any of the following apply:

Exclusion Criteria:

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (5 Sites)

Duke Cancer Institute Cary — Cary, North Carolina
Durham Veterans Administration Health Care System (DVAHCS) — Durham, North Carolina
Duke University Medical Center — Durham, North Carolina
Duke Women's Cancer Care Raleigh — Raleigh, North Carolina
Duke Raleigh Hospital — Raleigh, North Carolina

📞 Contact the Study Coordinator

Phone: (919) 668-3726

Email: RadOnc-Clinical_Trials@dm.duke.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Oligometastasis

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT) — Cleveland, Ohio
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial — Buffalo, New York

Explore by condition: All Oligometastasis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗